|
| | SB1497 Engrossed | | LRB103 26129 CPF 52485 b |
|
|
1 | | AN ACT concerning regulation.
|
2 | | Be it enacted by the People of the State of Illinois,
|
3 | | represented in the General Assembly:
|
4 | | Section 5. The Nursing Home Care Act is amended by |
5 | | changing Sections 1-112, 2-106, and 2-106.1 as follows:
|
6 | | (210 ILCS 45/1-112) (from Ch. 111 1/2, par. 4151-112)
|
7 | | Sec. 1-112.
"Emergency" means a situation, physical |
8 | | condition , or one or
more practices, methods , or operations |
9 | | which present imminent danger of death
or serious physical or |
10 | | mental harm to residents of a facility and are clinically |
11 | | documented in the resident's medical record .
|
12 | | (Source: P.A. 81-223.)
|
13 | | (210 ILCS 45/2-106) (from Ch. 111 1/2, par. 4152-106)
|
14 | | Sec. 2-106. Restraints. |
15 | | (a) For purposes of this Act, (i) a physical restraint is |
16 | | any
manual method or physical or
mechanical device, material, |
17 | | or equipment attached or adjacent to a
resident's body that |
18 | | the resident cannot remove easily and
restricts
freedom of |
19 | | movement or normal access to one's
body , and . Devices used for
|
20 | | positioning, including but not limited to bed rails,
gait |
21 | | belts, and cushions, shall not be considered to be restraints |
22 | | for
purposes of this Section;
(ii) a chemical restraint
is
any |
|
| | SB1497 Engrossed | - 2 - | LRB103 26129 CPF 52485 b |
|
|
1 | | drug used for discipline or convenience and not required to |
2 | | treat medical
symptoms. |
3 | | Devices used for
positioning, including, but not limited |
4 | | to, bed rails and
gait belts, shall not be considered to be |
5 | | physical restraints for
purposes of this Act unless the device |
6 | | is used to restrain or otherwise limit the patient's freedom |
7 | | to move. A device used for positioning must be requested by the |
8 | | resident, the resident's guardian, or the resident's |
9 | | authorized representative, or the need for that device must be |
10 | | physically demonstrated by the resident and documented in the |
11 | | resident's care plan. The physically demonstrated need of the |
12 | | resident for a device used for positioning must be revisited |
13 | | in every comprehensive assessment of the resident. |
14 | | The Department shall by rule, designate certain devices as
|
15 | | restraints,
including at least all those devices which have |
16 | | been determined
to be restraints by the United States |
17 | | Department of Health and Human Services
in
interpretive |
18 | | guidelines issued for the purposes of administering Titles |
19 | | XVIII and XIX of the Social Security Act.
|
20 | | (b) Neither restraints nor confinements shall be employed
|
21 | | for the purpose of punishment or for the convenience of any |
22 | | facility personnel.
No restraints or confinements shall be |
23 | | employed except as ordered
by a physician who documents the |
24 | | need for such restraints or confinements
in the
resident's |
25 | | clinical record.
|
26 | | (c) A restraint may be used only with the informed consent |
|
| | SB1497 Engrossed | - 3 - | LRB103 26129 CPF 52485 b |
|
|
1 | | of the
resident, the resident's guardian, or other authorized |
2 | | representative. A
restraint may be used only for specific |
3 | | periods, if it is the
least restrictive means necessary to |
4 | | attain and maintain the resident's highest
practicable |
5 | | physical, mental or psychosocial well-being, including brief
|
6 | | periods of time to provide necessary life-saving treatment. A |
7 | | restraint may be
used only after consultation with appropriate |
8 | | health professionals, such as
occupational or physical |
9 | | therapists, and a trial of less restrictive measures
has led |
10 | | to the determination that the use of less restrictive measures
|
11 | | would not attain or maintain the resident's highest |
12 | | practicable physical,
mental or psychosocial well-being.
|
13 | | However, if the resident needs emergency care, restraints may |
14 | | be used for brief
periods to
permit medical treatment to |
15 | | proceed unless the facility has notice that the
resident has |
16 | | previously made a valid refusal of the treatment in
question.
|
17 | | (d) A restraint may be applied only by a person trained in |
18 | | the application
of the particular type of restraint.
|
19 | | (e) Whenever a period of use of a restraint is initiated, |
20 | | the resident shall
be advised of his or her right to have a |
21 | | person or organization of his or
her
choosing,
including the |
22 | | Guardianship and Advocacy Commission, notified of the use of |
23 | | the
restraint. A recipient
who is under guardianship may |
24 | | request that a person or organization of his or
her choosing be |
25 | | notified of the restraint, whether or not the guardian
|
26 | | approves the notice.
If the resident so chooses, the facility |
|
| | SB1497 Engrossed | - 4 - | LRB103 26129 CPF 52485 b |
|
|
1 | | shall make the notification
within 24 hours, including any |
2 | | information
about
the period of time that the restraint is to |
3 | | be used.
Whenever the Guardianship and Advocacy Commission is |
4 | | notified that a resident
has been restrained, it shall contact |
5 | | the resident to determine the
circumstances of the restraint |
6 | | and whether further action is warranted.
|
7 | | (f) Whenever a restraint is used on a resident whose |
8 | | primary mode of
communication is sign language, the resident |
9 | | shall be permitted to have his or
her
hands free from restraint |
10 | | for brief periods each hour, except when this freedom
may
|
11 | | result in physical harm to the resident or others.
|
12 | | (g) The requirements of this Section are intended to |
13 | | control in any conflict
with the requirements of Sections
|
14 | | 1-126 and 2-108 of the Mental Health and Developmental |
15 | | Disabilities Code.
|
16 | | (Source: P.A. 97-135, eff. 7-14-11.)
|
17 | | (210 ILCS 45/2-106.1)
|
18 | | Sec. 2-106.1. Drug treatment.
|
19 | | (a) A resident shall not be given unnecessary drugs. An
|
20 | | unnecessary drug is any drug used in an excessive dose, |
21 | | including in
duplicative therapy; for excessive duration; |
22 | | without adequate
monitoring; without adequate indications for |
23 | | its use; or in the
presence of adverse consequences that |
24 | | indicate the drugs should be reduced or
discontinued. The |
25 | | Department shall adopt, by rule, the standards
for unnecessary
|
|
| | SB1497 Engrossed | - 5 - | LRB103 26129 CPF 52485 b |
|
|
1 | | drugs
contained in interpretive guidelines issued by the |
2 | | United States Department of
Health and Human Services for the |
3 | | purposes of administering Titles XVIII and XIX of
the Social |
4 | | Security Act.
|
5 | | (b) State laws, regulations, and policies related to
|
6 | | psychotropic medication are intended to ensure psychotropic |
7 | | medications are used only when the medication is appropriate |
8 | | to treat a resident's specific, diagnosed, and documented
|
9 | | condition and the medication is beneficial to the resident,
as |
10 | | demonstrated by monitoring and documentation of the resident's
|
11 | | response to the medication. |
12 | | (b-3) Except in the case of an emergency, psychotropic |
13 | | medication shall not be administered without the informed
|
14 | | consent of the resident or the resident's surrogate decision |
15 | | maker. Psychotropic medication shall only be given in both |
16 | | emergency and nonemergency situations if the diagnosis of the |
17 | | resident supports the benefit of the
medication and clinical |
18 | | documentation
in the resident's medical record supports the |
19 | | benefit of the
medication over the contraindications related |
20 | | to other
prescribed medications. "Psychotropic medication"
|
21 | | means medication that
is used for or listed as used for |
22 | | psychotropic, antidepressant, antimanic, or
antianxiety |
23 | | behavior modification or behavior management purposes in the |
24 | | latest
editions of the AMA Drug Evaluations or the Physician's |
25 | | Desk Reference. "Emergency" has the same meaning as in Section |
26 | | 1-112 of the Nursing Home Care Act. A facility shall (i) |
|
| | SB1497 Engrossed | - 6 - | LRB103 26129 CPF 52485 b |
|
|
1 | | document the alleged emergency in detail, including the facts |
2 | | surrounding the medication's need, and (ii) present this |
3 | | documentation to the resident and the resident's |
4 | | representative. The Department shall adopt, by rule, a |
5 | | protocol specifying how informed consent for psychotropic |
6 | | medication may be obtained or refused. The protocol shall |
7 | | require, at a minimum, a discussion between (i) the resident |
8 | | or the resident's surrogate decision maker and (ii) the |
9 | | resident's physician, a registered pharmacist, or a licensed |
10 | | nurse about the possible risks and benefits of a recommended |
11 | | medication and the use of standardized consent forms |
12 | | designated by the Department. The protocol shall include |
13 | | informing the resident, surrogate decision maker, or both of |
14 | | the existence of a copy of: the resident's care plan; the |
15 | | facility policies and procedures adopted in compliance with |
16 | | subsection (b-15) of this Section; and a notification that the |
17 | | most recent of the resident's care plans and the facility's |
18 | | policies are available to the resident or surrogate decision |
19 | | maker upon request. Each form designated or developed by the |
20 | | Department (i) shall be written in plain language, (ii) shall |
21 | | be able to be downloaded from the Department's official |
22 | | website or another website designated by the Department, (iii) |
23 | | shall include information specific to the psychotropic |
24 | | medication for which consent is being sought, and (iv) shall |
25 | | be used for every resident for whom psychotropic drugs are |
26 | | prescribed. The Department shall utilize the rules, protocols, |
|
| | SB1497 Engrossed | - 7 - | LRB103 26129 CPF 52485 b |
|
|
1 | | and forms developed and implemented under the Specialized |
2 | | Mental Health Rehabilitation Act of 2013 in effect on the |
3 | | effective date of this amendatory Act of the 101st General |
4 | | Assembly, except to the extent that this Act requires a |
5 | | different procedure, and except that the maximum possible |
6 | | period for informed consent shall be until: (1) a change in the |
7 | | prescription occurs, either as to type of psychotropic |
8 | | medication or an increase or decrease in dosage, dosage range, |
9 | | or titration schedule of the prescribed medication that was |
10 | | not included in the original informed consent; or (2) a |
11 | | resident's care plan changes. The Department may further amend |
12 | | the rules after January 1, 2021 pursuant to existing |
13 | | rulemaking authority. In addition to creating those forms, the |
14 | | Department shall approve the use of any other informed consent |
15 | | forms that meet criteria developed by the Department. At the |
16 | | discretion of the Department, informed consent forms may |
17 | | include side effects that the Department reasonably believes |
18 | | are more common, with a direction that more complete |
19 | | information can be found via a link on the Department's |
20 | | website to third-party websites with more complete |
21 | | information, such as the United States Food and Drug |
22 | | Administration's website. The Department or a facility shall |
23 | | incur no liability for information provided on a consent form |
24 | | so long as the consent form is substantially accurate based |
25 | | upon generally accepted medical principles and if the form |
26 | | includes the website links. |
|
| | SB1497 Engrossed | - 8 - | LRB103 26129 CPF 52485 b |
|
|
1 | | Informed consent shall be sought from the resident. For |
2 | | the purposes of this Section, "surrogate decision maker" means |
3 | | an individual representing the resident's interests as |
4 | | permitted by this Section. Informed consent shall be sought by |
5 | | the resident's guardian of the person if one has been named by |
6 | | a court of competent jurisdiction. In the absence of a |
7 | | court-ordered guardian, informed consent shall be sought from |
8 | | a health care agent under the Illinois Power of Attorney Act |
9 | | who has authority to give consent. If neither a court-ordered |
10 | | guardian of the person nor a health care agent under the |
11 | | Illinois Power of Attorney Act is available and the attending |
12 | | physician determines that the resident lacks capacity to make |
13 | | decisions, informed consent shall be sought from the |
14 | | resident's attorney-in-fact designated under the Mental Health |
15 | | Treatment Preference Declaration Act, if applicable, or the |
16 | | resident's representative. |
17 | | In addition to any other penalty prescribed by law, a |
18 | | facility that is found to have violated this subsection, or |
19 | | the federal certification requirement that informed consent be |
20 | | obtained before administering a psychotropic medication, shall |
21 | | thereafter be required to obtain the signatures of 2 licensed |
22 | | health care professionals on every form purporting to give |
23 | | informed consent for the administration of a psychotropic |
24 | | medication, certifying the personal knowledge of each health |
25 | | care professional that the consent was obtained in compliance |
26 | | with the requirements of this subsection.
|
|
| | SB1497 Engrossed | - 9 - | LRB103 26129 CPF 52485 b |
|
|
1 | | (b-5) A facility must obtain voluntary informed consent, |
2 | | in writing, from a resident or the resident's surrogate |
3 | | decision maker before administering or dispensing a |
4 | | psychotropic medication to that resident. When informed |
5 | | consent is not required for a change in dosage, the facility |
6 | | shall note in the resident's file that the resident was |
7 | | informed of the dosage change prior to the administration of |
8 | | the medication or that verbal, written, or electronic notice |
9 | | has been communicated to the resident's surrogate decision |
10 | | maker that a change in dosage has occurred. |
11 | | (b-10) No facility shall deny continued residency to a |
12 | | person on the basis of the person's or resident's, or the |
13 | | person's or resident's surrogate decision maker's, refusal of |
14 | | the administration of psychotropic medication, unless the |
15 | | facility can demonstrate that the resident's refusal would |
16 | | place the health and safety of the resident, the facility |
17 | | staff, other residents, or visitors at risk. |
18 | | A facility that alleges that the resident's refusal to |
19 | | consent to the administration of psychotropic medication will |
20 | | place the health and safety of the resident, the facility |
21 | | staff, other residents, or visitors at risk must: (1) document |
22 | | the alleged risk in detail; (2) present this documentation to |
23 | | the resident or the resident's surrogate decision maker, to |
24 | | the Department, and to the Office of the State Long Term Care |
25 | | Ombudsman; and (3) inform the resident or his or her surrogate |
26 | | decision maker of his or her right to appeal to the Department. |
|
| | SB1497 Engrossed | - 10 - | LRB103 26129 CPF 52485 b |
|
|
1 | | The documentation of the alleged risk shall include a |
2 | | description of all nonpharmacological or alternative care |
3 | | options attempted and why they were unsuccessful. |
4 | | (b-15) Within 100 days after the effective date of any |
5 | | rules adopted by the Department under subsection (b-3) (b) of |
6 | | this Section, all facilities shall implement written policies |
7 | | and procedures for compliance with this Section. When the |
8 | | Department conducts its annual survey of a facility, the |
9 | | surveyor may review these written policies and procedures and |
10 | | either: |
11 | | (1) give written notice to the facility that the |
12 | | policies or procedures are sufficient to demonstrate the |
13 | | facility's intent to comply with this Section; or |
14 | | (2) provide written notice to the facility that the |
15 | | proposed policies and procedures are deficient, identify |
16 | | the areas that are deficient, and provide 30 days for the |
17 | | facility to submit amended policies and procedures that |
18 | | demonstrate its intent to comply with this Section. |
19 | | A facility's failure to submit the documentation required |
20 | | under this subsection is sufficient to demonstrate its intent |
21 | | to not comply with this Section and shall be grounds for review |
22 | | by the Department. |
23 | | All facilities must provide training and education on the |
24 | | requirements of this Section to all personnel involved in |
25 | | providing care to residents and train and educate such |
26 | | personnel on the methods and procedures to effectively |
|
| | SB1497 Engrossed | - 11 - | LRB103 26129 CPF 52485 b |
|
|
1 | | implement the facility's policies. Training and education |
2 | | provided under this Section must be documented in each |
3 | | personnel file. |
4 | | (b-20) Upon the receipt of a report of any violation of |
5 | | this Section, the Department shall investigate and, upon |
6 | | finding sufficient evidence of a violation of this Section, |
7 | | may proceed with disciplinary action against the licensee of |
8 | | the facility. In any administrative disciplinary action under |
9 | | this subsection, the Department shall have the discretion to |
10 | | determine the gravity of the violation and, taking into |
11 | | account mitigating and aggravating circumstances and facts, |
12 | | may adjust the disciplinary action accordingly. |
13 | | (b-25) A violation of informed consent that, for an |
14 | | individual resident, lasts for 7 days or more under this |
15 | | Section is, at a minimum, a Type "B" violation. A second |
16 | | violation of informed consent within a year from a previous |
17 | | violation in the same facility regardless of the duration of |
18 | | the second violation is, at a minimum, a Type "B" violation. |
19 | | (b-30) Any violation of this Section by a facility may be |
20 | | enforced by an action brought by the Department in the name of |
21 | | the People of Illinois for injunctive relief, civil penalties, |
22 | | or both injunctive relief and civil penalties. The Department |
23 | | may initiate the action upon its own complaint or the |
24 | | complaint of any other interested party. |
25 | | (b-35) Any resident who has been administered a |
26 | | psychotropic medication in violation of this Section may bring |
|
| | SB1497 Engrossed | - 12 - | LRB103 26129 CPF 52485 b |
|
|
1 | | an action for injunctive relief, civil damages, and costs and |
2 | | attorney's fees against any facility responsible for the |
3 | | violation. |
4 | | (b-40) An action under this Section must be filed within 2 |
5 | | years of either the date of discovery of the violation that |
6 | | gave rise to the claim or the last date of an instance of a |
7 | | noncompliant administration of psychotropic medication to the |
8 | | resident, whichever is later. |
9 | | (b-45) A facility subject to action under this Section |
10 | | shall be liable for damages of up to $500 for each day after |
11 | | discovery of a violation that the facility violates the |
12 | | requirements of this Section. |
13 | | (b-55) The rights provided for in this Section are |
14 | | cumulative to existing resident rights. No part of this |
15 | | Section shall be interpreted as abridging, abrogating, or |
16 | | otherwise diminishing existing resident rights or causes of |
17 | | action at law or equity. |
18 | | (c) The requirements of
this Section are intended to |
19 | | control in a conflict
with the requirements of Sections 2-102 |
20 | | and 2-107.2
of the Mental Health and Developmental |
21 | | Disabilities Code with respect to the
administration of |
22 | | psychotropic medication.
|
23 | | (d) In this Section only, "licensed nurse" means an |
24 | | advanced practice registered nurse, a registered nurse, or a |
25 | | licensed practical nurse. |
26 | | (Source: P.A. 101-10, eff. 6-5-19; 102-646, eff. 8-27-21.)
|